VivoSeq
Oncology

Ovarian Neoplasm

36

Pipeline Programs

0

Active Trials

21

Companies Involved

Ovarian Neoplasm is a moderately active landscape with 36 programs across 21 companies. The most active players are Eastern Cooperative Oncology Group, Iovance Biotherapeutics, Inc., Regeneron. 19 therapies are approved with 3 more in late-stage development.

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

0/100

Mech. Concentration

7/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

75%

Small molecule

27 of 36 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody411%Protein / enzyme411%Antibody–drug conjugate13%

Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 100% of 37 pipeline programs.

Trial Status

1

clinical trials

Completed1 · 100%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)